Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MRT 2359

Next Previous
Drug Profile

MRT 2359

Alternative Names: MRT-2359

Latest Information Update: 13 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Monte Rosa Therapeutics
  • Class Antineoplastics; Carbamates; Ethers; Fluorobenzenes; Isoindoles; Ketones; Piperidines; Small molecules
  • Mechanism of Action Peptide-chain-release factor 3 degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I/II Diffuse large B cell lymphoma; HER2 negative breast cancer; HER2 positive breast cancer; Neuroendocrine tumours; Non-small cell lung cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 04 Aug 2026 Phase-II clinical trials in Prostate cancer (Hormone refractory, Combination therapy, Metastatic disease, Late-stage disease) in USA (PO) (NCT07745361)
  • 16 Mar 2026 Monte Rosa Therapeutics plans the phase II MODeFIRe-1 trial for Prostate cancer (Hormone-refractory, Metastatic disease, Combination therapy, Late-stage disease) (PO, Tablet), in the third quarter of 2026
  • 24 Feb 2026 Updated efficacy and adverse events data from a phase I/II trial in Prostate cancer released by Monte Rosa Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top